New Research Explores on Acute Heart Failure-Pipeline Review, H2 2016
Acute Heart Failure-Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Acute Heart Failure pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.
Complete report available @ Acute Heart Failure-Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Heart Failure
- The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Heart Failure
Reasons to buy
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amgen Inc. Capricor Therapeutics, Inc. Eli Lilly and Company Lee's Pharmaceutical Holdings Limited Novartis AG Ono Pharmaceutical Co., Ltd. PhaseBio Pharmaceuticals, Inc. Trevena, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 00:03
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home